Related Experiment Video
Updated: May 21, 2026

06:29
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
Tetraploidization increases sensitivity to Aurora B kinase inhibition
Miriam Marxer1, Charles E Foucar, Wing Yu Man
1Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong.
Cell Cycle (Georgetown, Tex.)
|June 23, 2012
Summary
Polyploid cancer cells are more sensitive to Aurora B kinase inhibitors, leading to apoptosis. Inhibiting Aurora B or cytokinesis effectively targets these polyploid cells, offering a potential anticancer strategy.
Area of Science:
- Cell Biology
- Cancer Biology
- Pharmacology
Background:
- Aurora kinases are frequently overexpressed in various cancers and are established targets for anticancer drug development.
- Polyploidization, an increase in chromosome sets, is a common characteristic observed in many malignant tumors.
- The yeast homolog of Aurora B kinase, IPL1, functions as a ploidy-specific lethality gene, suggesting a role for ploidy in sensitivity to kinase inhibition.
Purpose of the Study:
- To investigate the hypothesis that polyploidization sensitizes mammalian cells to Aurora kinase inhibition.
- To determine if tetraploid cells exhibit differential sensitivity to Aurora kinase inhibitors compared to diploid cells.
- To elucidate the underlying mechanisms responsible for sensitivity or resistance to Aurora kinase inhibition in polyploid cells.
Main Methods:
- Utilized two distinct models of diploid versus tetraploid cell lines, including a hepatocellular carcinoma cell line (Hep3B) and untransformed mouse fibroblasts.
- Administered two different Aurora B kinase inhibitors to assess their effects on tetraploid and diploid cells.
- Investigated the impact of Aurora A kinase inhibition on tetraploid cells.
- Induced polyploidy and mitotic defects using dihydrocytochalasin B to abolish cytokinesis.
Main Results:
- Tetraploid cells demonstrated significantly higher sensitivity to Aurora B kinase inhibition compared to their diploid counterparts.
- Apoptosis was effectively induced in tetraploid cells upon treatment with Aurora B inhibitors.
- Tetraploid cells were sensitive to Aurora B inhibition but showed no significant response to Aurora A inhibition.
- The observed sensitivity in tetraploid cells was attributed to mitotic slippage and subsequent excessive genome reduplication.
- Abolishing cytokinesis with dihydrocytochalasin B mimicked the effects of Aurora B inhibition in tetraploid cells.
Conclusions:
- Polyploidization sensitizes mammalian cells to Aurora B kinase inhibition.
- Inhibition of Aurora B kinase is a promising strategy for inducing apoptosis in polyploid cancer cells.
- Targeting cytokinesis represents an alternative approach to effectively promote apoptosis in polyploid cancer cells.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

